公开(公告)号：US11377438B2

公开(公告)日：2022-07-05

申请号：US16669598

申请日：2019-10-31

Applicant: Merck Sharp & Dohme Corp.

Inventor： Ashok Arasappan ,  Ian M. Bell ,  Michael J. Breslin ,  Christopher James Bungard ,  Christopher S. Burgey ,  Harry R. Chobanian ,  Jason M. Cox ,  Anthony T. Ginnetti ,  Deodial Guy Guiadeen ,  Kristen L. G. Jones ,  Mark E. Layton ,  Hong Liu ,  Jian Liu ,  James J. Perkins ,  Shawn J. Stachel ,  Linda M. Suen-Lai ,  Zhe Wu

IPC: C07D401/12 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D491/04 ,  C07D471/08 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

公开(公告)号：US20210403457A1

公开(公告)日：2021-12-30

申请号：US17347639

申请日：2021-06-15

Applicant: Merck Sharp & Dohme Corp.

Inventor： Ashok Arasappan ,  Ian M. Bell ,  Christopher James Bungard ,  Christopher S. Burgey ,  Jason M. Cox ,  Michael J. Kelly, III ,  Mark E. Layton ,  Hong Liu ,  Jian Liu ,  James J. Perkins ,  Akshay A. Shah ,  Michael David VanHeyst ,  Zhe Wu

IPC: C07D403/12 ,  C07D233/32 ,  C07D401/14 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12 ,  C07D417/14 ,  C07D413/12 ,  C07D513/04 ,  C07D471/08 ,  C07D471/04

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

公开(公告)号：US11802122B2

公开(公告)日：2023-10-31

申请号：US17347639

申请日：2021-06-15

Applicant: Merck Sharp & Dohme Corp.

Inventor： Ashok Arasappan ,  Ian M. Bell ,  Christopher James Bungard ,  Christopher S. Burgey ,  Jason M. Cox ,  Michael J. Kelly, III ,  Mark E. Layton ,  Hong Liu ,  Jian Liu ,  James J. Perkins ,  Akshay A. Shah ,  Michael David VanHeyst ,  Zhe Wu

IPC: C07D403/12 ,  C07D233/32 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D513/04 ,  A61K31/4166 ,  A61P25/00 ,  A61P25/04 ,  A61P29/00

CPC classification number: C07D403/12 ,  C07D233/32 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D513/04

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

公开(公告)号：US20210387966A1

公开(公告)日：2021-12-16

申请号：US17289123

申请日：2019-10-31

Applicant: Merck Sharp & Dohme Corp.

Inventor： Ashok Arasappan ,  Ian M. Bell ,  Michael J. Breslin ,  Christopher James Bungard ,  Christopher S. Burgey ,  Harry R. Chobanian ,  Jason M. Cox ,  Anthony T. Ginnetti ,  Deodial Guy Guiadeen ,  Kristen L. G. Jones ,  Mark E. Layton ,  Hong Liu ,  Jian Liu ,  James J. Perkins ,  Shawn J. Stachel ,  Linda M. Suen-Lai ,  Zhe Wu

IPC: C07D401/14 ,  C07D471/04 ,  C07D413/14 ,  C07D471/08 ,  C07D495/04 ,  C07D401/12 ,  C07D487/04 ,  C07D491/048

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

公开(公告)号：US20230227441A1

公开(公告)日：2023-07-20

申请号：US18009306

申请日：2021-06-14

Applicant: Ashok ARASAPPAN ,  Ian M. BELL ,  Christopher James BUNGARD ,  Christopher S. BURGEY ,  Jason M. COX ,  Deodial Guy GUIADEEN ,  Michael J. KELLY ,  Mark E. LAYTON ,  Hong LIU ,  Jian LIU ,  James T. OLSEN ,  James J. PERKINS ,  Jeffrey W. SCHUBERT ,  Akshay A. SHAH ,  Michael D. VANHEYST ,  Zhe WU ,  Shawn J. STACHEL ,  MERCK SHARP & DOHME CORP.

Inventor： Ashok Arasappan ,  Ian M. Bell ,  Christopher James Bungard ,  Christopher S. Burgey ,  Jason Michael Cox ,  Deodial Guy Guiadeen, III ,  Michael J. Kelly, III ,  Mark E. Layton ,  Hong Liu ,  Jian Liu ,  James T. Olsen ,  James J. Perkins ,  Jeffrey W. Schubert ,  Akshay A. Shah ,  Shawn J. Stachel ,  Michael David VanHeyst ,  Zhe Wu

IPC: C07D413/12 ,  C07D263/24 ,  C07D417/12

CPC classification number: C07D413/12 ,  C07D263/24 ,  C07D417/12

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

公开(公告)号：US20220119363A1

公开(公告)日：2022-04-21

申请号：US17289152

申请日：2019-10-28

Applicant: Merck Sharp & Dohme Corp.

Inventor： Michael J. Breslin ,  Christopher James Bungard ,  Harry R. Chobanian ,  Kristen L. G. Jones ,  Mark E. Layton ,  Jian Liu ,  James J. Perkins ,  Jeffrey William Schubert ,  Shawn J. Stachel ,  Linda M. Suen-Lai ,  Zhe Wu

IPC: C07D401/04 ,  C07D213/82 ,  C07D401/14 ,  C07D487/18 ,  C07D498/08 ,  C07D513/04 ,  C07D413/04 ,  C07D417/04 ,  C07D487/08 ,  C07D491/107 ,  C07D498/04 ,  C07D491/048 ,  C07D417/14 ,  C07D409/14 ,  C07D405/14 ,  C07D403/04 ,  C07D451/02

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.